Clinical Trial Update: Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC) [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing intermittent 4/2 dosing versus continuous dosing of sunitinib malate as first-line therapy for metastatic renal cell carcinoma has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED | Results posted: 2011-09-05